Moderna (MRNA)
(Delayed Data from NSDQ)
$63.93 USD
+0.29 (0.46%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $63.85 -0.08 (-0.13%) 5:32 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.93 USD
+0.29 (0.46%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $63.85 -0.08 (-0.13%) 5:32 PM ET
4-Sell of 5 4
F Value C Growth C Momentum D VGM
Zacks News
Matador Resources (MTDR) Up 50.4% MTD: What's Driving It?
by Zacks Equity Research
Improving oil prices on encouraging coronavirus vaccine news aid Matador Resources (MTDR).
Cyclical Stocks Pop on Vaccine Progress: 5 Solid Buys
by Tirthankar Chakraborty
Positive news on the COVID-19 vaccine front revitalized the U.S. economy and vis-a-vis cyclical stocks like General Motors (GM), Delta Apparel (DLA) and Deere (DE).
5 Top-Performing ETFs of Last Week
by Sanghamitra Saha
Last week for Wall Street was all about vaccine optimism marred somewhat by rising virus cases and fears of further lockdowns.
Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
4 Sectors to Prosper in Thanksgiving Week
by Sanghamitra Saha
Back-to-back positive vaccine updates have offered sweet surprises to Wall Street from the start of the Thanksgiving month this year.
Markets Up on Sunny Holiday Outlook
by Mark Vickery
The NRF announced it expects U.S. holiday shopping season to grow 5.2% year over year, based on pent-up demand and higher U.S. savings rates during the pandemic.
AstraZeneca-Oxford Vaccine at 70% Efficacy
by Mark Vickery
One very positive piece of news from the AZN-Oxford study is that the doses may be refrigerated at normal cooler temperatures.
Stock Market News for Nov 20, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Thursday on hopes of restarting of Congressional negotiations for a fresh tranche of fiscal stimulus.
EOG Resources (EOG) Up 32.8% MTD: What's Behind the Rally?
by Zacks Equity Research
Improving oil prices on positive coronavirus vaccine results aid EOG Resources (EOG).
5 Top Stocks to Buy Amid Potential Economic Recovery
by Zacks Equity Research
With the U.S. economy showing steady signs of a recovery and promising vaccine trials, it will be prudent to invest in fundamentally sound stocks like Crocs (CROX) and FedEx (FDX).
Small Caps at the Forefront of Market Rally: 5 ETF Winners
by Sweta Killa
While the rally has been broad-based across all the market caps, small-caps stocks, as indicated by the Russell 2000 Index, has been outperforming and is hitting new all-time highs.
Pfizer/BioNTech COVID-19 Vaccine Shows Final Efficacy of 95%
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 95% effective in final analysis.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
U.S. Crude Hits its Highest Price in 2 Months: Here's Why
by Nilanjan Choudhury
Some of the top gainers of the S&P 500 during the past month include energy-related names like Devon Energy (DVN), Baker Hughes Company (BKR), Diamondback Energy (FANG) and Marathon Oil (MRO).
Bull Market to Surge on Vaccine Snapback
by Kevin Cook
How 5% GDP and 25% EPS growth could fuel a run to S&P 4,500 in 2021.
Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.
Bet on Quality ETFs as Vaccine Hope & Coronavirus Cases Rise
by Sweta Killa
Quality ETFs could enjoy smooth trading and generate market-beating returns in the current market environment.
Airline Stock Roundup: LUV's Bleak Update, Azul's Q3 Loss, ALGT's Traffic & More
by Maharathi Basu
Southwest Airlines (LUV) expects operating revenues to be down 60-65% in both November and December. Meanwhile, Azul (AZUL) performs badly in Q3 due to coronavirus-led revenue weakness.
Why Cyclical Sector ETFs Are Roaring to All-Time Highs
by Sweta Killa
Vaccine optimism has spurred buying in cyclical sectors, which are tied to economic activities.
Moderna (MRNA) COVID-19 Vaccine MAA Under Rolling Review in EU
by Zacks Equity Research
Moderna (MRNA) announces start of rolling review of its regulatory application, seeking marketing authorization for its coronavirus vaccine candidate.
Small-Cap ETF (VTWO) Hits New 52-Week High
by Sweta Killa
This small-cap ETF hits a new 52-week high. Are more gains in store for this ETF?
Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Ternium, Virgin Galactic, Moderna, Pfizer and Johnson & Johnson highlighted as Zacks Bull and Bear of the Day
Schlumberger (SLB) Up 11.3% in a Day: What's Behind the Rally?
by Nilanjan Banerjee
Improving fuel demand on positive coronavirus vaccine results aids Schlumberger (SLB).
Dow ETF Hits New Highs on Vaccine Optimism: 5 Best Stocks
by Sweta Killa
The Dow Jones hit all-time highs since February, marking its fastest bear market recovery in 30 years.
Disappointing Retail Sales Data for October
by Zacks Equity Research
Disappointing Retail Sales Data for October.